Fetal globin gene inducers: Novel agents and new potential

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 158-164

  Perrine, Susan P ^a,b,c   Castaneda, Serguei A ^a   Chui, David H K ^a   Faller, Douglas V ^a   Berenson, Ronald J ^b,c   Siritanaratku, Noppadol ^d   Fucharoen, Suthat ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HemaQuest Pharmaceuticals   (United States)

^c HemaQuest   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

erythropoiesis; fetal globin; quantitative trait loci; short chain fatty acids; thalassemia

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALPHA GLOBIN; AZACITIDINE; BUTYRIC ACID; ERYTHROPOIETIN; GAMMA GLOBIN; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; SODIUM 2,2 DIMETHYLBUTYRATE; UNCLASSIFIED DRUG;

ANEMIA; BETA THALASSEMIA; CARCINOGENICITY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; ERYTHROPOIESIS; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GLOBIN GENE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; PROTEIN SYNTHESIS; QUANTITATIVE TRAIT LOCUS;

EID: 77955906235     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05593.x     Document Type: Conference Paper

References (40)

1. Steinberg, M.H. & G.P. Rodgers. 2001. Pharmacologicmodulation of fetal hemoglobin. Med. (Baltimore) 80: 328-344.
2. Perrine, S.P. 2008. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr. Ann. 37: 339-346.
3. Gallo, E., P.Massaro, R.Miniero, et al. 1979. The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia. Br. J. Haematol. 41: 211-221.
4. Schrier, S.L. 1997. Pathobiology of thalassemic erythrocytes. Curr Opin. Hematol. 4: 75-78.
5. Stamatoyannopoulos, G. 2005. Control of globin gene expression during development and erythroid differentiation. Exp. Hematol. 33: 259-271.
6. Centis, F., L. Tabellini, G. Lucarelli, et al. 2000. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with betathalassemia major. Blood 96: 3624-3629.
7. Mathias, L.A., T.C. Fisher, L. Zeng, et al. 2000. Ineffective erythropoiesis in beta-thalassemiamajor is due to apoptosis at the polychromatophilic normoblast stage. Exp. Hematol. 28: 1343-1353.
8. Pootrakul, P., P. Sirankapracha, S. Hemsorach, et al. 2000. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 96: 2606-2612.
9. Collins, A.F., H.A. Pearson, P. Giardina, et al. 1995. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85: 43-49.
10. Perrine, S.P., G.D. Ginder, D.V. Faller, et al. 1993. A shortterm trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.N.Engl. J.Med. 328: 81-86.
11. Cao, H., G. Stamatoyannopoulos & M. Jung. 2004. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 103: 701-709.
12. Domenica Cappellini, M.,G.Graziadei, L. Ciceri, et al. 2000. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol. Dis. 26: 105-111.
13. Reich, S., C. Buhrer, G. Henze, et al. 2000. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood 96: 3357-3363.
14. Dunbar, C., W. Travis, Y.W. Kan, et al. 1989. 5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies. Br. J. Haematol. 72: 467-468.
15. Hajjar, F.M.&H.A. Pearson. 1994. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J. Pediatr. 125: 490-492.
16. Singer, S.T., F.A. Kuypers, N.F. Olivieri, et al. 2005. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br. J. Haematol. 131: 378-388.
17. Fucharoen, S., N. Siritanaratkul, P. Winichagoon, et al. 1996. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in betathalassemia/ hemoglobin E disease. Blood 87: 887-892.
18. Lowrey, C.H.&A.W.Nienhuis. 1993. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N. Engl. J. Med. 329: 845-848.
19. Ley, T.J., J. DeSimone, N.P. Anagnou, et al. 1982. 5- azacytidine selectively increases gamma-globin synthesis in a patient with beta+thalassemia. N. Engl. J.Med. 307: 1469-1475.
20. Saunthararajah, Y., C.A. Hillery, D. Lavelle, et al. 2003. Effects of 5-aza-2-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102: 3865-3870.
21. Perrine, S.P., R. Mankidy, M.S. Boosalis, et al. 2009. ErythroidKruppel- like factor (EKLF) is recruited to the gammaglobin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur. J. Haematol. 82: 466-476.
22. Bourantas, K., G. Economou & J. Georgiou. 1997. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Eur. J. Haematol. 58: 22-25.
23. Nisli, G., K. Kavakli, C. Vergin, et al. 1996. Recombinant human erythropoietin trial in thalassemia intermedia. J. Trop. Pediatr. 42: 330-334.
24. Rachmilewitz, E.A. & M. Aker. 1998. The role of recombinant human erythropoietin in the treatment of thalassemia. Ann. N.Y. Acad. Sci. 850: 129-138.
25. Galanello, R., S. Barella, M.P. Turco, et al. 1994. Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients. Blood 83: 561-565.
26. Ikuta T, Kan YW, Swerdlow PS, et al. 1998 Alterations in protein-DNA interactions in the- globin gene promoter in response to butyrate therapy. Blood 92: 2924-2933.
27. Perrine, S., D.V. Faller, L. Shen, et al. 2009. HQK-1001 has additiveHbF-inducing activity in combinationwith hydroxyurea and decitabine [abstract]. Blood 114: 977.
28. Pace, B.S., G.L. White, G.J. Dover, et al. 2002. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 100: 4640-4648.
29. Castaneda, S., M.S. Boosalis,D. Emery, et al. 2005. Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol. Dis. 35: 217-226.
30. Perrine, S.,W.C.Welch, J. Keefer, et al. 2008. Phase 1 clinical testing of HQK-1001, a novel oral fetal globin gene inducer [abstract]. Blood 112: 130.
31. Boosalis,M.S., R. Bandyopadhyay, E.H. Bresnick, et al. 2001. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 97: 3259-3267.
32. Thein, S.L., S. Menzel, M. Lathrop, et al. 2009. Control of fetal hemoglobin: new insights emerging fromgenomics and clinical implications. Hum. Mol. Genet. 18: R216-R223.
33. Labie, D., J. Pagnier, C. Lapoumeroulie, et al. 1985. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc. Natl. Acad. Sci. USA 82: 2111-2114.
34. Nuinoon, M., W. Makarasara, T. Mushiroda, et al. 2010. A genome-wide association identified the common genetic variants influence disease severity in beta?- thalassemia/hemoglobin E. Hum. Genet. 127: 303-314.
35. Jiang, J., S. Best, S. Menzel, et al. 2006. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108: 1077-1083.
36. Garner, C., J.Mitchell, T.Hatzis, et al. 1998.Haplotypemapping of amajor quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am. J. Hum. Genet. 62: 1468-1474.
37. Chen, Z., H.Y. Luo, M.H. Steinberg, et al. 2009. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol. Dis. 42: 144-149.
38. Sankaran, V.G., J. Xu, T. Ragoczy, et al. 2009. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460: 1093-1097.
39. Bohacek, R., M.S. Boosalis, C. McMartin, et al. 2006. Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem. Biol. Drug. Des. 67: 318-328.
40. Mankidy, R., D.V. Faller, R. Mabaera, et al. 2006. Shortchain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood 108: 3179-3186.